Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 214,000 | 136,000 | 207,067 | 159,933 | 167,000 |
| Cost of Goods | 34,000 | 30,000 | 29,009 | 27,991 | 23,000 |
| Gross Profit | 180,000 | 106,000 | 178,058 | 131,942 | 144,000 |
| Operating Expenses | 255,000 | 275,000 | 291,177 | 303,823 | 252,000 |
| Operating Income | -75,000 | -169,000 | -113,110 | -170,890 | -108,000 |
| Interest Expense | 22,000 | 21,000 | 19,852 | 14,148 | 14,000 |
| Other Income | 6,000 | 6,000 | 5,502 | 5,498 | 8,000 |
| Pre-tax Income | -91,000 | -184,000 | -127,460 | -179,540 | -114,000 |
| Income Tax | 1,000 | 1,000 | 1,127 | 873 | 1,000 |
| Net Income Continuous | -92,000 | -185,000 | -128,587 | -180,413 | -115,000 |
| Net Income | $-92,000 | $-185,000 | $-128,587 | $-180,413 | $-115,000 |
| EPS Basic Total Ops | -0.90 | -1.84 | -1.28 | -1.81 | -1.17 |
| EPS Basic Continuous Ops | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 |
| EPS Diluted Total Ops | -0.90 | -1.84 | -1.28 | -1.81 | -1.17 |
| EPS Diluted Continuous Ops | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.84 | -1.29 | -1.81 | -1.17 |
| EBITDA(a) | $-67,000 | $-162,000 | $-104,841 | $-163,159 | $-100,000 |